Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.54 |
| ▸ | CNR2 | P34972 | 8/20 | 0.54 |
| ▸ | KRAS | P01116 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.46 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.46 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.46 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415335 | 1.00 | CNR1 (0.54) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL23415339 | 0.87 | KRAS (0.51) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL29901337 | 0.84 | KRAS (0.56) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL29888689 | 0.84 | KRAS (0.56) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL23415350 | 0.84 | KRAS (0.56) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL23415323 | 0.82 | CNR1 (0.48) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL29888416 | 0.82 | CNR1 (0.48) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL23415476 | 0.81 | KRAS (0.51) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL29901300 | 0.81 | KRAS (0.51) | CNR1CNR2KRASEGFRHMOX2 | |
| SCHEMBL28833844 | 0.80 | KRAS (0.54) | CNR1CNR2KRASEGFRHMOX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| EP-4065231-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | CNR1 3958/4885CNR2 4218/4885KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.